| Document |
Document Title |
|
WO/2021/068950A1 |
Disclosed in the present invention are an amide compound and the medical use thereof as a STING inhibitor. Specifically, disclosed is a compound represented by formula I or formula II, or a pharmaceutically acceptable salt or ester or so...
|
|
WO/2021/065893A1 |
The purpose of the present invention is to provide a novel low-molecular-weight compound that exhibits agonistic activity on an orexin receptor and is expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the li...
|
|
WO/2021/060277A1 |
Provided are, inter alia, compounds useful as aminating agents capable of introducing an amino group protected by a deprotectable protecting group into a wide range of substates under relatively moderate conditions, an aminating agent ha...
|
|
WO/2021/060276A1 |
Provided, inter alia, is a fluorinating agent that can selectively produce a monofluorination product through preferential synthesis of the monofluorination product over a difluorination product, in a fluorination reaction in which a flu...
|
|
WO/2021/041600A3 |
Heat sensitive recording material, recording sheets formed from heat sensitive recording material, and methods for forming images using heat sensitive recording material are provided. An exemplary heat sensitive recording material includ...
|
|
WO/2021/055849A1 |
The application relates to lipids of Formula (A-1) and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include such a lipid as well as additional lipids such as phospholipids, structural lipids, and...
|
|
WO/2021/042080A1 |
A mitochondrial uncoupler and method of treating a disorder using the same are provided. The mitochondrial uncoupler includes any compound having a structure according to Formula I, where R1 includes a dihalophenyl, R2 includes a substit...
|
|
WO/2021/041866A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and thei...
|
|
WO/2021/039463A1 |
A novel dopant according to the present disclosure contains an anion represented by formula (1) and a counter cation. In formula (1), each of R1 and R2 represents at least one group selected from among a nitro group, a cyano group, an ac...
|
|
WO/2021/036256A1 |
The present application is suitable for use in the technical field of drug synthesis, and provides a method for synthesizing an HIV protease inhibitor intermediate compounds. The method comprises subjecting compound 1a to an asymmetric t...
|
|
WO/2021/039244A1 |
Provided is an actinic ray-sensitive or radiation-sensitive resin composition with which a pattern having excellent LWR performance can be obtained even when the composition has been stored for a long period of time. Also provided are a ...
|
|
WO/2021/039824A1 |
An RNA methyltransferase inhibitor containing at least one type of compound selected from the group consisting of sulfonamide-based compounds represented by general formula (1) and pyrazoline-based compounds represented by general formul...
|
|
WO/2021/035031A1 |
Inhibitors of Glycerol 3-Phosphate Acyltransferase (GPAT) are provided; and methods of use in the treatment of cancer; and treatment of conditions relating to metabolic syndrome, hyperlipidemia, infection and inflammation.
|
|
WO/2021/029158A1 |
The purpose of the present invention is to provide: a sulfonamide compound which has a high decomposition rate in response to near-ultraviolet rays and which generates a superacid bis-sulfonamide, and which is highly soluble in a resist ...
|
|
WO/2021/028512A1 |
The present invention provides new arylsulfonamide compounds having the general formula (I), wherein L, R1, R2, R3 and R4are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods ...
|
|
WO/2021/026257A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
|
|
WO/2021/020481A1 |
The present invention is a method for producing an intermediate of iguratimod derivatives, a method for producing iguratimod, iguratimod having a novel crystal structure, and a method for producing the same. The present invention can rai...
|
|
WO/2021/021951A1 |
Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/012721A1 |
Disclosed in the present invention are a naphthalenesulfonamide compound, a preparation method, and an application. The naphthalenesulfonamide compound provided by the present invention can interfere with Keap1-Nrf2 binding and activate ...
|
|
WO/2021/016333A1 |
The present disclosure provides pharmaceutical compositions comprising aryl sulfonamide Stat3 small molecule inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use for treating cancer.
|
|
WO/2021/009566A1 |
Described herein are N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds of formula (I) wherein R1 is formulae (II), (III), (IV), (V), (VI), (VII), (VIII) or (...
|
|
WO/2021/011592A1 |
Scaffold compounds are used to design small molecule compounds and structure- activity relationship studies identify inhibitors of inflammation· Methods include pharmaceutical compositions of the small molecule compounds to inhibit, pre...
|
|
WO/2021/009568A1 |
Provided herein are benzenesulfonamide derivatives having Formula (III), pharmaceutical compositions comprising said compounds, and method for using said compounds for disrupting proteins/polypeptides, protein/polypeptide function, and f...
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2021/009567A1 |
Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2021/007478A1 |
Provided herein are sulfone compounds, for example, a compound of Formula A, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant there...
|
|
WO/2021/003084A1 |
A compound has Formula I: (I). R1 is hydrogen, hydroxy, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkyamino, heterocyclyl, aryl, heteroaryl, -NR7R8, -CO-R10, or -NH-CO-R10; L is a bond, a heterocyclic bivalent gr...
|
|
WO/2020/261752A1 |
One problem addressed by the present invention is to provide a method for producing an active light sensitive or radiation sensitive resin composition which is capable of forming a pattern that is suppressed in defects. Another problem a...
|
|
WO/2020/254558A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2020/255585A1 |
The present invention provides a method for purifying a compound that generates an acid when irradiated with active light or radiation, said method being capable of reducing the content of metal impurities, while having excellent recover...
|
|
WO/2020/257037A1 |
Provided is a pharmaceutical composition comprising: (a) granules comprising dichlorphenamide, or a pharmaceutically acceptable salt thereof, and one or more intragranular excipients; and an extragranular portion comprising at least one ...
|
|
WO/2020/222675A1 |
This invention relates to an active ingredient of a pharmaceutical composition, said active ingredient being in the form of micronized crystals of monoclinic symmetry (MCMS) of sodium {[4-({[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluoroph...
|
|
WO/2020/214560A1 |
A method of producing purified bis(fluorosulfonyl) imide includes providing a liquid mixture including bis(fluorosulfonyl) imide and fluorosulfonic acid and then contacting the liquid mixture with gaseous ammonia. The gaseous ammonia rea...
|
|
WO/2020/201326A1 |
The present invention relates to novel aminoguanidine hydrazone-derivatives of Formula (I) which are effective as retromer stabilizers and useful as neuroprotecting drugs. The invention also relates to pharmaceutical compositions compris...
|
|
WO/2020/202072A1 |
The present invention relates to a compound of Formula la, lb and Ic, (Formula Ia) a pharmaceutical composition comprising the same and their use in the treatment or prevention of pathological conditions associated to depolarizing GABAer...
|
|
WO/2020/199757A1 |
The present invention relates to a sulfonylbenzamide derivative, a preparation method therefor, and a medical use thereof. Specifically, disclosed are a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvat...
|
|
WO/2020/205789A1 |
Electrolytes and polymers for a lithium battery can include a fluorinated aryl sulfonimide salt or fluorinated aryl sulfonimide polymer.
|
|
WO/2020/205470A1 |
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
|
|
WO/2020/204041A1 |
Provided is a colored dispersion that contains (A) a dye derivative, (B) a water-insoluble dye, (C) a dispersant, and water, wherein the (A) component contains an anthraquinone-based compound represented by formula (a1), the (C) componen...
|
|
WO/2020/194272A1 |
The present application relates to fluorinated benzylsulfonamide hydroxamic acid compounds of Formula I and/or pharmaceutically acceptable salt, solvate and/or prodrug thereof : (I) for use as a inhibitor of HDAC6. The application also r...
|
|
WO/2020/193419A1 |
The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.
|
|
WO/2020/193322A1 |
The present invention relates to compounds of Formula (I), wherein R1 and R2 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula ...
|
|
WO/2020/184336A1 |
Provided is a liquid metal complex having oxygen-absorbing ability and containing: a cobalt acacene complex or a derivative thereof; and an ionic liquid in which an ionic ligand having an amine structure and a counter ion thereof are pai...
|
|
WO/2020/176686A1 |
The present invention concerns novel methods of treatment for venetoclax-resistant acute myeloid leukemia, particularly in subjects with a low expression of TP53 protein or expression of TP53 protein associated with a mutation of the TP5...
|
|
WO/2020/175495A1 |
Provided is a method for producing a salt by reacting M+X- with YH so as to generate XH and M+Y-, and then removing the generated XH so as to obtain M+Y-. M+X- is a salt of a cation represented by M+ and an anion represented by X-. M+Y- ...
|
|
WO/2020/168290A1 |
Provided herein are methods for treating a disease, such as cancer, the methods including administering one or more N-aryl benezenesulfonamides or analogs thereof to a subject in need thereof.
|
|
WO/2020/157771A1 |
The present invention relates to preparation of pyrazoles. This invention further relates to a continuous flow micro-total process system for preparation of celecoxib, a COX-2 selective non-steroidal anti-inflammatory drug, and analogs t...
|
|
WO/2020/157126A1 |
The present invention relates to a class of novel compounds of general formula (I), their use as medicaments and pharmaceutical compositions comprising them. Specifically, the compounds of the invention are useful as voltage-gated potass...
|
|
WO/2020/160140A1 |
Disclosed in certain embodiments is a method of treating a pulmonary disease comprising administering a therapeutically effective amount of a Matrix Metalloproteinase (MMP) Inhibitor to a patient in need thereof wherein the pulmonary dis...
|
